SARS-CoV-2 - Azithromycin - Therapeutic Candidates

SARS-CoV-2 - Azithromycin - Therapeutic Candidates


Azithromycin is a macrolide antibiotic. This broad-spectrum antibiotic of the azalide group is a derivative of erythromycin. Azithromycin is indicated for the treatment of certain types of mild to moderate infections caused by bacteria. Most commonly, it is used to treat ear infections such as otitis media, throat and lung infections such as pharyngitis and pneumonia, and certain skin infections. Azithromycin is also prescribed to patients with cystic fibrosis because they are particularly susceptible to respiratory infections.
A recent study, in the context of the Covid-19 epidemic currently affecting many countries around the world, sought to investigate the effect of azithromycin in combination with hydroxychloroquine. The interest in azithromycin came from the fact that the rate of Covid-19 infection was low in a large cohort of patients with cystic fibrosis, many of whom are on azithromycin therapy.

Search result : 277 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 38
  • Biochemicals 231
  • Inhibitor/Antagonist/Agonist 42
  • Buffers and reagents 2
  • cell culture products 2
  • Assay 3
  • Cell culture 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
257209-500mg
 500mg 
162716-100mg
 100mg 
257209-100mg
 100mg 
257209-50mg
 50mg 
M2426-10mg
 10mg 
331-20461-2
 25mg 
M2426-50mg
 50mg 
M2426-100mg
 100mg 
331-20461-1
 10mM(in1mLDMSO) 
331-20461-3
 50mg 
TRC-N137478-25MG
 25mg 
TRC-N292400-100MG
 100mg 
257285-10g
 10g 
257285-25g
 25g 
257285-500mg
 500mg 
257285-5g
 5g 
257285-1g
 1g 
TRC-A927004-10MG
 10mg 
442034-1mg
 1mg 
458788-2.5mg
 2.5mg